
|Articles|July 15, 2004
Verteporfin-maker QLT to merge with Atrix
Vancouver, British Columbia-An $855 million deal will unite verteporfin (Visudyne) developer QLT Inc. and Atrix Laboratories Inc. to build QLT's business and accelerate strategic initiatives.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement




























